{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T21:27:32Z","timestamp":1793482052694,"version":"4.5.0"},"reference-count":153,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,1,12]],"date-time":"2020-01-12T00:00:00Z","timestamp":1578787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Huntington\u2019s disease (HD) is a progressive neurological disease that is inherited in an autosomal fashion. The cause of disease pathology is an expansion of cytosine-adenine-guanine (CAG) repeats within the huntingtin gene (HTT) on chromosome 4 (4p16.3), which codes the huntingtin protein (mHTT). The common symptoms of HD include motor and cognitive impairment of psychiatric functions. Patients exhibit a representative phenotype of involuntary movement (chorea) of limbs, impaired cognition, and severe psychiatric disturbances (mood swings, depression, and personality changes). A variety of symptomatic treatments (which target glutamate and dopamine pathways, caspases, inhibition of aggregation, mitochondrial dysfunction, transcriptional dysregulation, and fetal neural transplants, etc.) are available and some are in the pipeline. Advancement in novel therapeutic approaches include targeting the mutant huntingtin (mHTT) protein and the HTT gene. New gene editing techniques will reduce the CAG repeats. More appropriate and readily tractable treatment goals, coupled with advances in analytical tools will help to assess the clinical outcomes of HD treatments. This will not only improve the quality of life and life span of HD patients, but it will also provide a beneficial role in other inherited and neurological disorders. In this review, we aim to discuss current therapeutic research approaches and their possible uses for HD.<\/jats:p>","DOI":"10.3390\/brainsci10010043","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T04:05:51Z","timestamp":1578888351000},"page":"43","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Therapeutic Advances for Huntington\u2019s Disease"],"prefix":"10.3390","volume":"10","author":[{"given":"Ashok","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Genetics, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow 226014, UP, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8035-9181","authenticated-orcid":false,"given":"Vijay","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Yeungnam University, Gyeongsan, Gyeongbuk 38541, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kritanjali","family":"Singh","sequence":"additional","affiliation":[{"name":"Central Research Station, Subharti Medical College, Swami Vivekanand Subharti University, Meerut 250002, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"PG Department of Botany, Nalanda College, Bihar Sharif, Magadh University, Bihar 824234, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Sam","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Yeungnam University, Gyeongsan, Gyeongbuk 38541, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Mi","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Yeungnam University, Gyeongsan, Gyeongbuk 38541, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Joo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Yeungnam University, Gyeongsan, Gyeongbuk 38541, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/WCO.0000000000000116","article-title":"An update on Huntington\u2019s disease: From the gene to the clinic","volume":"27","author":"Kim","year":"2014","journal-title":"Curr. Opin. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: Natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ebiom.2018.03.031","article-title":"Effect of Trinucleotide Repeats in the Huntington\u2019s Gene on Intelligence","volume":"31","author":"Lee","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s12035-015-9662-8","article-title":"Huntington\u2032s Disease: Relationship Between Phenotype and Genotype","volume":"54","author":"Sun","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1474-4422(17)30161-8","article-title":"Identification of genetic variants associated with Huntington\u2019s disease progression: A genome-wide association study","volume":"16","author":"Moss","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s11064-007-9463-1","article-title":"Glutamate uptake is reduced in prefrontal cortex in Huntington\u2019s disease","volume":"33","author":"Hassel","year":"2008","journal-title":"Neurochem. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.tibs.2013.05.003","article-title":"Huntington\u2019s disease: Underlying molecular mechanisms and emerging concepts","volume":"38","author":"Labbadia","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neuro.2017.01.005","article-title":"Risk factors for the onset and progression of Huntington disease","volume":"61","author":"Chao","year":"2017","journal-title":"Neurotoxicology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1474-4422(18)30294-1","article-title":"Biological and clinical manifestations of juvenile Huntington\u2019s disease: A retrospective analysis","volume":"17","author":"Fusilli","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Horizon Investigators Of The Huntington Study Group, and European Huntington\u2019s Disease Network (2013). A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. JAMA Neurol., 70, 25\u201333.","DOI":"10.1001\/2013.jamaneurol.382"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington\u2019s disease: A clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00415-012-6415-8","article-title":"Substance abuse may be a risk factor for earlier onset of Huntington disease","volume":"259","author":"Byars","year":"2012","journal-title":"J. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1212\/WNL.0000000000003661","article-title":"Substance abuse may hasten motor onset of Huntington disease: Evaluating the Enroll-HD database","volume":"88","author":"Schultz","year":"2017","journal-title":"Neurology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1212\/WNL.0b013e3182648b65","article-title":"Measures of growth in children at risk for Huntington disease","volume":"79","author":"Lee","year":"2012","journal-title":"Neurology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.biopsych.2011.07.030","article-title":"Striatal volume contributes to the prediction of onset of Huntington disease in incident cases","volume":"71","author":"Aylward","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e1939","DOI":"10.1212\/WNL.0000000000007355","article-title":"Brain structure in juvenile-onset Huntington disease","volume":"92","author":"Tereshchenko","year":"2019","journal-title":"Neurology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2217\/nmt-2017-0019","article-title":"A survey-based study identifies common but unrecognized symptoms in a large series of juvenile Huntington\u2019s disease","volume":"7","author":"Moser","year":"2017","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.gene.2014.11.022","article-title":"Huntington\u2019s disease: An update of therapeutic strategies","volume":"556","author":"Kumar","year":"2015","journal-title":"Gene"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/jnnp-2012-304636","article-title":"Prevalence of adult Huntington\u2019s disease in the UK based on diagnoses recorded in general practice records","volume":"84","author":"Evans","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/mds.25717","article-title":"Multisource ascertainment of Huntington disease in Canada: Prevalence and population at risk","volume":"29","author":"Fisher","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-12-801893-4.00001-8","article-title":"Genetics of Huntington disease","volume":"144","author":"Nance","year":"2017","journal-title":"Handb. Clin. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199405193302001","article-title":"A worldwide study of the Huntington\u2019s disease mutation. The sensitivity and specificity of measuring CAG repeats","volume":"330","author":"Kremer","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1590\/S0100-879X2003000200002","article-title":"Glutamine and glutamate as vital metabolites","volume":"36","author":"Newsholme","year":"2003","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1006\/nbdi.1998.0168","article-title":"Intranuclear neuronal inclusions in Huntington\u2019s disease and dentatorubral and pallidoluysian atrophy: Correlation between the density of inclusions and IT15 CAG triplet repeat length","volume":"4","author":"Becher","year":"1998","journal-title":"Neurobiol. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.spen.2006.11.006","article-title":"Trinucleotide repeat disorders","volume":"14","author":"Lutz","year":"2007","journal-title":"Semin. Pediatr. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1006\/exnr.1997.6520","article-title":"Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration","volume":"146","author":"Palfi","year":"1997","journal-title":"Exp. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"189307","DOI":"10.1155\/2015\/189307","article-title":"Riluzole stimulates BDNF release from human platelets","volume":"2015","author":"Turck","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","article-title":"Riluzole in Huntington\u2019s disease: A 3-year, randomized controlled study","volume":"62","author":"Landwehrmeyer","year":"2007","journal-title":"Ann. Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"M\u00fcller, T., and Riederer, P. (2004). The N-methyl-D-aspartate antagonist memantine retards progression of Huntington\u2019s disease. Focus on Extrapyramidal Dysfunction, Springer.","DOI":"10.1007\/978-3-7091-0579-5"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.brainres.2006.08.035","article-title":"Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington\u2019s disease","volume":"1118","author":"Lee","year":"2006","journal-title":"Brain Res."},{"key":"ref_34","first-page":"1353","article-title":"Clinical experience with risperidone and memantine in the treatment of Huntington\u2019s disease","volume":"98","author":"Cankurtaran","year":"2006","journal-title":"J. Natl. Med. Assoc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.nbd.2013.11.013","article-title":"Chronic blockade of extrasynaptic NMDA receptors ameliorates synaptic dysfunction and pro-death signaling in Huntington disease transgenic mice","volume":"62","author":"Dau","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/nm.2056","article-title":"Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin","volume":"15","author":"Okamoto","year":"2009","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2010.01.008","article-title":"Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington\u2019s disease mice","volume":"65","author":"Milnerwood","year":"2010","journal-title":"Neuron"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1750-1326-5-18","article-title":"Tetrabenazine is neuroprotective in Huntington\u2019s disease mice","volume":"5","author":"Wang","year":"2010","journal-title":"Mol. Neurodegener."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","article-title":"Current Pharmacological Approaches to Reduce Chorea in Huntington\u2019s Disease","volume":"77","author":"Coppen","year":"2017","journal-title":"Drugs"},{"key":"ref_40","first-page":"123","article-title":"Management of Huntington\u2019s disease: Role of tetrabenazine","volume":"7","author":"Serpino","year":"2011","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40734-017-0051-5","article-title":"Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease","volume":"4","author":"Claassen","year":"2017","journal-title":"J. Clin. Mov. Disord."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/77528","article-title":"Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease","volume":"6","author":"Chen","year":"2000","journal-title":"Nat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1212\/01.WNL.0000049936.85487.7A","article-title":"Minocycline for Huntington\u2019s disease: An open label study","volume":"60","author":"Bonelli","year":"2003","journal-title":"Neurology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00004850-200411000-00004","article-title":"Neuroprotection in Huntington\u2019s disease: A 2-year study on minocycline","volume":"19","author":"Bonelli","year":"2004","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/mds.20018","article-title":"Minocycline in Huntington\u2019s disease: A pilot study","volume":"19","author":"Thomas","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature01301","article-title":"Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders","volume":"421","author":"Sanchez","year":"2003","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.brainresrev.2006.08.001","article-title":"Congo red and protein aggregation in neurodegenerative diseases","volume":"53","author":"Frid","year":"2007","journal-title":"Brain Res. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0306-4522(00)00391-2","article-title":"Amyloid-like inclusions in Huntington\u2019s disease","volume":"100","author":"McGowan","year":"2000","journal-title":"Neuroscience"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nm985","article-title":"Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease","volume":"10","author":"Tanaka","year":"2004","journal-title":"Nat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41419-018-0749-9","article-title":"Mechanism of neuroprotection by trehalose: Controversy surrounding autophagy induction","volume":"9","author":"Lee","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Fernandez-Estevez, M.A., Casarejos, M.J., Lopez Sendon, J., Garcia Caldentey, J., Ruiz, C., Gomez, A., Perucho, J., de Yebenes, J.G., and Mena, M.A. (2014). Trehalose reverses cell malfunction in fibroblasts from normal and Huntington\u2019s disease patients caused by proteosome inhibition. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090202"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3233\/JHD-130074","article-title":"An independent study of the preclinical efficacy of C2-8 in the R6\/2 transgenic mouse model of Huntington\u2019s disease","volume":"2","author":"Wang","year":"2013","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"16685","DOI":"10.1073\/pnas.0707842104","article-title":"A small-molecule therapeutic lead for Huntington\u2019s disease: Preclinical pharmacology and efficacy of C2-8 in the R6\/2 transgenic mouse","volume":"104","author":"Chopra","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/ng1362","article-title":"Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease","volume":"36","author":"Ravikumar","year":"2004","journal-title":"Nat. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"ra103","DOI":"10.1126\/scisignal.2005633","article-title":"Huntingtin promotes mTORC1 signaling in the pathogenesis of Huntington\u2019s disease","volume":"7","author":"Pryor","year":"2014","journal-title":"Sci. Signal."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1212\/WNL.0000000000004209","article-title":"The CREST-E study of creatine for Huntington disease: A randomized controlled trial","volume":"89","author":"Hersch","year":"2017","journal-title":"Neurology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1212\/WNL.0000000000003478","article-title":"A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease","volume":"88","author":"McGarry","year":"2017","journal-title":"Neurology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/mds.26308","article-title":"Ethyl-eicosapentaenoic acid treatment in Huntington\u2019s disease: A placebo-controlled clinical trial","volume":"30","author":"Ferreira","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/j.1460-9568.2006.04686.x","article-title":"Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington\u2019s disease knock-in striatal cells","volume":"23","author":"Mao","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/hmg\/ddq464","article-title":"Meclizine is neuroprotective in models of Huntington\u2019s disease","volume":"20","author":"Gohil","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1074\/jbc.M410210200","article-title":"Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington\u2019s disease","volume":"280","author":"Gardian","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1073\/pnas.0804249105","article-title":"The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington\u2019s disease transgenic mice","volume":"105","author":"Thomas","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington\u2019s disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"19176","DOI":"10.1073\/pnas.0606373103","article-title":"ESET\/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington\u2019s disease","volume":"103","author":"Ryu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","article-title":"Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington\u2019s disease","volume":"29","author":"Southwell","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_67","first-page":"E3136","article-title":"Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6\/2 mice","volume":"109","author":"Herrmann","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nm.3793","article-title":"Therapeutic genome editing: Prospects and challenges","volume":"21","author":"Cox","year":"2015","journal-title":"Nat. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1172\/JCI92087","article-title":"CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington\u2019s disease","volume":"127","author":"Yang","year":"2017","journal-title":"J. Clin. Investg."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: Molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/mt.2008.50","article-title":"AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington\u2019s disease","volume":"16","author":"Franich","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/hum.2013.200","article-title":"Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington\u2019s disease","volume":"25","author":"Stanek","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/gt.2017.14","article-title":"MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain","volume":"24","author":"Samaranch","year":"2017","journal-title":"Gene Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/hmg\/ddl017","article-title":"Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington\u2019s disease by ubiquilin","volume":"15","author":"Wang","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Safren, N., El Ayadi, A., Chang, L., Terrillion, C.E., Gould, T.D., Boehning, D.F., and Monteiro, M.J. (2014). Ubiquilin-1 overexpression increases the lifespan and delays accumulation of Huntingtin aggregates in the R6\/2 mouse model of Huntington\u2019s disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087513"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/emboj\/18.1.85","article-title":"In vivo newly translated polypeptides are sequestered in a protected folding environment","volume":"18","author":"Thulasiraman","year":"1999","journal-title":"EMBO J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1073\/pnas.1119472109","article-title":"Subunit order of eukaryotic TRiC\/CCT chaperonin by cross-linking, mass spectrometry, and combinatorial homology modeling","volume":"109","author":"Kalisman","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/mds.26174","article-title":"A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington\u2019s disease","volume":"30","author":"Reilmann","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1527-3458.2007.00018.x","article-title":"Pharmacological properties of BN82451: A novel multitargeting neuroprotective agent","volume":"13","author":"Chabrier","year":"2007","journal-title":"CNS Drug Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1471-4159.2003.t01-1-01868.x","article-title":"Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington\u2019s disease","volume":"86","author":"Klivenyi","year":"2003","journal-title":"J. Neurochem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.cell.2006.04.026","article-title":"Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin","volume":"125","author":"Graham","year":"2006","journal-title":"Cell"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"9158","DOI":"10.1074\/jbc.273.15.9158","article-title":"Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract","volume":"273","author":"Wellington","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_84","first-page":"1382","article-title":"Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease","volume":"70","author":"Marder","year":"2013","journal-title":"JAMA Neurol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.pharmthera.2005.04.008","article-title":"The therapeutic role of creatine in Huntington\u2019s disease","volume":"108","author":"Ryu","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","article-title":"Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2019dG","volume":"66","author":"Hersch","year":"2006","journal-title":"Neurology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1212\/WNL.0000000000000187","article-title":"PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease","volume":"82","author":"Rosas","year":"2014","journal-title":"Neurology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1212\/01.WNL.0000090629.40891.4B","article-title":"Creatine supplementation in Huntington\u2019s disease: A placebo-controlled pilot trial","volume":"61","author":"Verbessem","year":"2003","journal-title":"Neurology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-7091-0579-5_13","article-title":"Coenzyme Q10 serum levels in Huntington\u2019s disease","volume":"68","author":"Andrich","year":"2004","journal-title":"J. Neural Transm. Suppl."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","article-title":"Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington\u2019s disease","volume":"22","author":"Ferrante","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1471-4159.2009.06074.x","article-title":"Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson\u2019s and Huntington\u2019s diseases","volume":"109","author":"Yang","year":"2009","journal-title":"J. Neurochem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"8755","DOI":"10.1074\/jbc.R100062200","article-title":"The biochemistry of n-3 polyunsaturated fatty acids","volume":"277","author":"Jump","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"20804","DOI":"10.1074\/jbc.M202387200","article-title":"Neuroprotective effect of eicosapentaenoic acid in hippocampus of rats exposed to gamma-irradiation","volume":"277","author":"Lonergan","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"34239","DOI":"10.1074\/jbc.M205289200","article-title":"Apoptotic changes in the aged brain are triggered by interleukin-1beta-induced activation of p38 and reversed by treatment with eicosapentaenoic acid","volume":"277","author":"Martin","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1212\/01.wnl.0000169025.09670.6d","article-title":"Ethyl-EPA in Huntington disease: A double-blind, randomized, placebo-controlled trial","volume":"65","author":"Puri","year":"2005","journal-title":"Neurology"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Huntington Study Group TREND-HD Investigators (2008). Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: The TREND-HD study. Arch. Neurol., 65, 1582\u20131589.","DOI":"10.1001\/archneur.65.12.1582"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1002\/mds.21632","article-title":"Sodium phenylbutyrate in Huntington\u2019s disease: A dose-finding study","volume":"22","author":"Hogarth","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/hmg\/ddm064","article-title":"Modulation of nucleosome dynamics in Huntington\u2019s disease","volume":"16","author":"Stack","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s13311-013-0206-5","article-title":"Epigenetic mechanisms of neurodegeneration in Huntington\u2019s disease","volume":"10","author":"Lee","year":"2013","journal-title":"Neurotherapeutics"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1172\/JCI45130","article-title":"Oligonucleotide therapeutic approaches for Huntington disease","volume":"121","author":"Sah","year":"2011","journal-title":"J. Clin. Investg."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ymthe.2018.02.002","article-title":"Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic","volume":"26","author":"Miniarikova","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington\u2019s disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1749-6632.2009.04975.x","article-title":"Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA","volume":"1175","author":"Hu","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","article-title":"Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington\u2019s disease mice","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.21569","article-title":"Sustained effects of nonallele-specific Huntingtin silencing","volume":"65","author":"Drouet","year":"2009","journal-title":"Ann. Neurol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13023-016-0405-3","article-title":"The P42 peptide and Peptide-based therapies for Huntington\u2019s disease","volume":"11","author":"Marelli","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3233\/JHD-160222","article-title":"Modern Genome Editing Technologies in Huntington\u2019s Disease Research","volume":"6","author":"Malankhanova","year":"2017","journal-title":"J. Huntingt. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/978-1-4939-7825-0_21","article-title":"CRISPR\/Cas9-Mediated Genome Editing for Huntington\u2019s Disease","volume":"1780","author":"Vachey","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","article-title":"CRISPR\/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo","volume":"25","author":"Monteys","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/978-1-4939-9784-8_17","article-title":"Gene Therapy for Huntington\u2019s Disease Using Targeted Endonucleases","volume":"2056","author":"Dabrowska","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.omtn.2019.07.009","article-title":"CRISPR-Cas9-Mediated Genome Editing Increases Lifespan and Improves Motor Deficits in a Huntington\u2019s Disease Mouse Model","volume":"17","author":"Ekman","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0378-1119(92)90121-5","article-title":"RNase H-mediated inhibition of translation by antisense oligodeoxyribonucleotides: Use of backbone modification to improve specificity","volume":"121","author":"Larrouy","year":"1992","journal-title":"Gene"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/mt.2016.136","article-title":"Integrated Safety Assessment of 2\u2019-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers","volume":"24","author":"Crooke","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/JHD-130057","article-title":"Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington\u2019s disease","volume":"2","author":"Stanek","year":"2013","journal-title":"J. Huntingt. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene \/ allele-specific silencing of mutant huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.1605731113","article-title":"Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy","volume":"113","author":"Hammond","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting Huntingtin Expression in Patients with Huntington\u2019s Disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41536-019-0066-7","article-title":"Combination of stem cell and gene therapy ameliorates symptoms in Huntington\u2019s disease mice","volume":"4","author":"Cho","year":"2019","journal-title":"NPJ Regen. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40035-017-0101-9","article-title":"RNAi mechanisms in Huntington\u2019s disease therapy: siRNA versus shRNA","volume":"6","author":"Aguiar","year":"2017","journal-title":"Transl. Neurodegener."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1126\/science.1250127","article-title":"Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy","volume":"345","author":"Naryshkin","year":"2014","journal-title":"Science"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1021\/acs.jmedchem.6b00459","article-title":"Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine to Treat Spinal Muscular Atrophy","volume":"59","author":"Ratni","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.nmd.2018.10.001","article-title":"The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy","volume":"29","author":"Kletzl","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrd.2018.133","article-title":"Therapeutic approaches to Huntington disease: From the bench to the clinic","volume":"17","author":"Caron","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00415-006-0198-8","article-title":"Apoptotic cascades as possible targets for inhibiting cell death in Huntington\u2019s disease","volume":"253","author":"Pattison","year":"2006","journal-title":"J. Neurol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s13668-013-0041-7","article-title":"Mediterranean Diet and Minimizing Neurodegeneration","volume":"2","author":"Sofi","year":"2013","journal-title":"Curr. Nutr. Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jalz.2014.11.009","article-title":"MIND diet associated with reduced incidence of Alzheimer\u2019s disease","volume":"11","author":"Morris","year":"2015","journal-title":"Alzheimers Dement."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40478-018-0518-0","article-title":"Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease","volume":"6","author":"Ehrnhoefer","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1172\/JCI27607","article-title":"Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase","volume":"116","author":"Canals","year":"2006","journal-title":"J. Clin. Investg."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Menalled, L.B., Kudwa, A.E., Oakeshott, S., Farrar, A., Paterson, N., Filippov, I., Miller, S., Kwan, M., Olsen, M., and Beltran, J. (2014). Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6\/2 and zQ175 mouse models of Huntington\u2019s disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0099520"},{"key":"ref_130","first-page":"1","article-title":"Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington\u2019s Disease","volume":"7","author":"Waters","year":"2018","journal-title":"J. Hunt. Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.nbd.2018.12.022","article-title":"Pridopidine stabilizes mushroom spines in mouse models of Alzheimer\u2019s disease by acting on the sigma-1 receptor","volume":"124","author":"Ryskamp","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","article-title":"Pridopidine for the treatment of motor function in patients with Huntington\u2019s disease (MermaiHD): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Landwehrmeyer","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1474-4422(18)30391-0","article-title":"Safety and efficacy of pridopidine in patients with Huntington\u2019s disease (PRIDE-HD): A phase 2, randomised, placebo-controlled, multicentre, dose-ranging study","volume":"18","author":"Reilmann","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1093\/hmg\/ddw238","article-title":"Pridopidine activates neuroprotective pathways impaired in Huntington Disease","volume":"25","author":"Geva","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1471-4159.2005.03047.x","article-title":"Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington\u2019s disease","volume":"93","author":"Pineda","year":"2005","journal-title":"J. Neurochem."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1111\/jcmm.12604","article-title":"Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6\/2 mouse model","volume":"19","author":"Squitieri","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Huntington Study Group HART Investigators (2013). A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington\u2019s disease. Mov. Disord., 28, 1407\u20131415.","DOI":"10.1002\/mds.25362"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1212\/WNL.0000000000001214","article-title":"Triheptanoin improves brain energy metabolism in patients with Huntington disease","volume":"84","author":"Adanyeguh","year":"2015","journal-title":"Neurology"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/archneurol.2009.334","article-title":"A randomized, placebo-controlled trial of latrepirdine in Huntington disease","volume":"67","author":"Kieburtz","year":"2010","journal-title":"Arch. Neurol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1523\/JNEUROSCI.4262-04.2005","article-title":"Amantadine inhibits NMDA receptors by accelerating channel closure during channel block","volume":"25","author":"Blanpied","year":"2005","journal-title":"J. Neurosci"},{"key":"ref_141","first-page":"55","article-title":"Amantadine: A review of use in child and adolescent psychiatry","volume":"22","author":"Hosenbocus","year":"2013","journal-title":"J. Can. Acad Child. Adolesc. Psychiatry"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1212\/WNL.59.5.694","article-title":"Huntington\u2019s disease: A randomized, controlled trial using the NMDA-antagonist amantadine","volume":"59","author":"Morris","year":"2002","journal-title":"Neurology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2165\/00003495-200363190-00009","article-title":"Lamotrigine: A review of its use in bipolar disorder","volume":"63","author":"Goldsmith","year":"2003","journal-title":"Drugs"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Huang, Y.Y., Liu, Y.C., Lee, C.T., Lin, Y.C., Wang, M.L., Yang, Y.P., Chang, K.Y., and Chiou, S.H. (2016). Revisiting the Lamotrigine-Mediated Effect on Hippocampal GABAergic Transmission. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17071191"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/15622970701332520","article-title":"Lamotrigine in motor and mood symptoms of Huntington\u2019s disease","volume":"9","author":"Shen","year":"2008","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bcp.12512","article-title":"An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington\u2019s disease","volume":"79","author":"Sussmuth","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"S47.004","DOI":"10.1212\/WNL.82.10_supplement.S47.004","article-title":"Safety and Tolerability of Selisistat for the Treatment of Huntington\u2019s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (S47.004)","volume":"82","author":"Reilmann","year":"2014","journal-title":"Neurology"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"10671","DOI":"10.1073\/pnas.162362299","article-title":"Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington\u2019s disease","volume":"99","author":"Keene","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.expneurol.2016.06.008","article-title":"Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons","volume":"283","author":"Ehrnhoefer","year":"2016","journal-title":"Exp. Neurol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1007\/s12035-018-1393-1","article-title":"Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease","volume":"56","author":"Yusof","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"31652","DOI":"10.1038\/srep31652","article-title":"Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease","volume":"6","author":"Hong","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JHD-159003","article-title":"Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington\u2019s Disease","volume":"4","author":"Mazarei","year":"2015","journal-title":"J. Huntingt. Dis."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1074\/jbc.M708192200","article-title":"Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment","volume":"283","author":"Giorgini","year":"2008","journal-title":"J. Biol. Chem."}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/10\/1\/43\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:04:30Z","timestamp":1760364270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/10\/1\/43"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,12]]},"references-count":153,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["brainsci10010043"],"URL":"https:\/\/doi.org\/10.3390\/brainsci10010043","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints201912.0261.v1","asserted-by":"object"}]},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,12]]}}}